The Rising Tide of Lisata: Examining the Phenomenon The Rising Tide of Lisata: Examining the Phenomenon
Lisata Therapeutics, Inc.‘s LSTA flagship pipeline candidate is certepetide, once known as LSTA1, an innovative treatment for various solid tumors. Recently, Lisata revealed promising data from a preclinical study on certepetide for intrahepatic cholangiocarcinoma, a challenging cancer type with poor outcomes. The study demonstrated improved …